Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma (NASDAQ: IPHA) announced the selection of abstracts for presentation at the European Hematology Association (EHA) Congress 2025 in Milan, Italy. The first abstract features IPH6501, their ANKET® therapy targeting CD20 B cells for relapsed/refractory Non-Hodgkin Lymphoma, which will be presented in a poster session on June 14, 2025. Additionally, an abstract about SAR'514/IPH6401, developed in partnership with Sanofi for Multiple Myeloma treatment, was accepted for online publication.

Innate Pharma (IPHA) reported Q1 2025 business update with significant pipeline developments. Key highlights include a €15 million investment from Sanofi and pipeline progress across multiple programs. The company achieved a major milestone with FDA Breakthrough Therapy Designation for lacutamab in treating relapsed/refractory Sézary syndrome. The first patient was dosed in Phase 1 study for IPH4502, their Nectin-4 ADC candidate for advanced solid tumors. Financial position remains strong with €72.5 million cash position as of March 31, 2025 (excluding €15M from Sanofi), extending runway to mid-2026. Notable developments in their ANKET® platform include ongoing trials for IPH6501 in B-NHL and strategic changes in the Sanofi partnership, including the termination of the 2016 agreement for IPH6101 and refocusing of SAR'514/IPH6401 towards autoimmune indications.

Innate Pharma (IPHA) has disclosed its latest share and voting rights data as of May 5, 2025. The company's share structure includes 92,176,373 ordinary shares, along with 6,489 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. The difference between theoretical and exercisable voting rights is due to treasury shares with suspended voting rights. The AGAP 2016 shares carry specific voting rights (130 for AGAP 2016-1 and 111 for AGAP 2016-2), while AGAP 2017 shares have no voting rights attached.

Innate Pharma (IPHA) has scheduled a conference call and webcast for Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT to provide a business update for Q1 2025. Key executives participating in the call include CEO Jonathan Dickinson, CMO Sonia Quaratino, COO Yannis Morel, and CFO Frédéric Lombard.

The company's management team will also conduct investor meetings in New York and Boston from May 13-14, 2025. The webcast will be accessible through the company's website, with a replay available for 90 days following the event.

Innate Pharma has announced the filing of two important regulatory documents for the year ending December 31, 2024. The company has submitted its 2024 Universal Registration Document to the French market authority (AMF) and its annual report on Form 20-F to the U.S. Securities and Exchange Commission (SEC).

The Universal Registration Document, available in French, can be accessed through both the company's website and the AMF's website. Similarly, the Form 20-F annual report is accessible via Innate Pharma's website and the SEC's website.

Innate Pharma, which trades on both Euronext Paris (IPH) and Nasdaq (IPHA), completed these filings on April 30, 2025, fulfilling its regulatory obligations in both European and American markets.

Innate Pharma presented new preclinical data for IPH4502, their novel antibody drug conjugate targeting Nectin-4, at the AACR 2025 Annual Meeting. The drug showed superior anti-tumor activity compared to enfortumab vedotin (EV) in various cancer models.

Key findings include:

• Better performance in urothelial carcinoma models with low Nectin-4 expression
• Effectiveness against EV-resistant tumors
• Strong activity in multiple cancers including triple-negative breast cancer, head and neck, and esophageal cancers

IPH4502 is currently in Phase 1 clinical trials for advanced solid tumors, with initial clinical data expected in 2026. The drug's enhanced internalization, cytotoxicity, and bystander killing effect suggest potential improved clinical benefits in areas with unmet medical needs.

Innate Pharma (Nasdaq: IPHA) has disclosed its latest share and voting rights data as of April 25, 2025. The company reported 92,175,723 ordinary shares outstanding, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. The theoretical voting rights include those attached to AGAP 2016, comprising 130 voting rights for AGAP 2016-1 and 111 voting rights for AGAP 2016-2, while AGAP 2017 carries no voting rights.

Innate Pharma (IPHA) has announced a significant capital increase of €15 million through a strategic investment from Sanofi. The investment involves Sanofi subscribing to 8,345,387 new ordinary shares at €1.7974 per share, based on the volume-weighted average price on April 23, 2025.

The proceeds will be utilized for general corporate purposes, including extending the company's cash runway to support pipeline execution and long-term value creation. This investment builds upon their existing partnership, which includes the development of BCMA targeting ANKET® program in autoimmune indications.

Following the capital increase, Sanofi-Aventis Participations will hold a 9.05% stake in Innate Pharma, becoming one of the major shareholders alongside Novo Nordisk A/S (10.65%), Medimmune (8.12%), and Bpifrance Participations (6.93%).

Innate Pharma (IPHA) announces significant changes in its collaboration with Sanofi. The company will regain rights to CD123 targeting ANKET® SAR443579/IPH6101, currently in development for AML. The Phase 1/2 study showed promising results with 5 complete responses at 1 mg/kg and durable CR in 3 patients.

Sanofi plans a strategic investment of up to €15M in Innate through a capital increase, subject to market conditions. While Sanofi will discontinue BCMA targeting ANKET® (SAR'514/IPH6401) in multiple myeloma, it will redirect its development towards autoimmune indications.

The 2022 research collaboration agreement remains intact, with Sanofi maintaining rights to develop IPH62 (B7-H3 targeting program) and retaining an option for one additional ANKET® target. Innate remains eligible for over €1 billion in R&D and commercial milestones.